- Home
- STOK
as 09-17-2025 4:00pm EST
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 1.3B | IPO Year: | 2019 |
| Target Price: | $26.60 | AVG Volume (30 days): | 893.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.35 - $24.60 | Next Earning Date: | 11-04-2025 |
| Revenue: | $199,893,000 | Revenue Growth: | 1218.82% |
| Revenue Growth (this year): | 416.54% | Revenue Growth (next year): | -82.92% |
Stock Insider Trading Activity of Stoke Therapeutics Inc. (STOK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kaye Edward M. MD | STOK | Director | Sep 3 '25 | Sell | $20.13 | 45,996 | $925,858.08 | 91,585 | |
| Allan Jonathan | STOK | GENERAL COUNSEL & CORP SEC | Sep 3 '25 | Sell | $20.07 | 6,345 | $127,316.87 | 11,831 | |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Sep 2 '25 | Sell | $19.87 | 5,501 | $109,325.22 | 18,469 | |
| Kaye Edward M. MD | STOK | Director | Sep 2 '25 | Sell | $20.14 | 14,860 | $299,259.60 | 91,585 | |
| Allan Jonathan | STOK | GENERAL COUNSEL & CORP SEC | Sep 2 '25 | Sell | $20.14 | 14,922 | $300,491.77 | 11,831 | |
| Kaye Edward M. MD | STOK | Director | Aug 29 '25 | Sell | $20.00 | 1,029 | $20,580.00 | 91,585 | |
| Allan Jonathan | STOK | GENERAL COUNSEL & CORP SEC | Aug 29 '25 | Sell | $20.00 | 850 | $17,000.00 | 11,831 | |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Aug 18 '25 | Sell | $18.24 | 2,805 | $51,157.59 | 18,469 | |
| Kaye Edward M. MD | STOK | N/A | Aug 18 '25 | Sell | $18.24 | 12,126 | $221,153.99 | 91,585 | |
| Allan Jonathan | STOK | GENERAL COUNSEL & CORP SEC | Aug 18 '25 | Sell | $18.24 | 1,683 | $30,694.55 | 11,831 |
Latest Stoke Therapeutics Inc. News
STOK Breaking Stock News: Dive into STOK Ticker-Specific Updates for Smart Investing
Simply Wall St.
7 days ago
Stoke Therapeutics (STOK) Unveils Promising Data For Dravet Syndrome Drug
Business Wire
3 months ago
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
4 months ago
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference
Zacks
4 months ago
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates
Business Wire
4 months ago
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
Zacks
5 months ago
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Investor's Business Daily
5 months ago
Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat?
Simply Wall St.
5 months ago
Is There An Opportunity With Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 49% Undervaluation?
Compare STOK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STOK Stoke Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.